Anastassiya Stepanovich-Falke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Anastassiya Stepanovich-Falke has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ruth Zimmermann
Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
2 shared publications - Sandra Dudareva
Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
2 shared publications Aibek Bekbolotov
Affiliation Republican Center for Viral Hepatitis und HIV/AIDS Control at the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan
1 shared publicationAida Karagulova
Affiliation Bishkek City AIDS Center, Bishkek, Kyrgyzstan
1 shared publicationAidana Kenzhekarieva
Affiliation Republican Center for Viral Hepatitis und HIV/AIDS Control at the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan
1 shared publicationAigul Solpueva
Affiliation Republican Center for Viral Hepatitis und HIV/AIDS Control at the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1) , 1087
Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016–2021
Background: Hepatitis B virus (HBV) infection remains one of the most common infectious diseases globally and can be exacerbated by coinfection with hepatitis D virus (HDV). In Germany, the incidence of hepatitis is reported annually through mandatory notification data. Nevertheless, these data lack information on hepatitis prevalence and testing coverage. We evaluated whether statutory health insurance claims data are suitable for continuous monitoring of key hepatitis indicators and whether they can complement existing HBV and HDV surveillance with reliable, population-based estimates. Methods: We conducted a population-based cohort study using anonymised claims data from an age- and gender-representative sample from the InGef (Institute for Applied Health research) database between 2016 and 2021. We retrospectively analysed monitoring indicators for HBV and HDV -including annual prevalent infections within the respective analysis year, incidence of newly detected HBV infections (defined using a 3-year diagnosis-free interval) and the number of persons tested- based on coded diagnoses among individuals with access to healthcare services. Results were extrapolated to the German total population. Results: Between 1,996 and 2,066 persons per 100,000 population were tested annually for at least one HBV marker (HBsAg or Anti-HBc), with 97% undergoing HBsAg testing only. The proportion of annual prevalent HBV infections ranged from 0.14% to 0.15% between 2016 and 2020. Incidence of newly detected HBV infections (3-year diagnosis-free interval) declined from 13.5 per 100,000 in 2019 to 8.9 per 100,000 in 2020. The proportion of prevalent HDV infections among HBV-positive persons varied from 4.5 to 6.4%. Conclusions: Claims data provide a viable basis for continuous monitoring of selected hepatitis indicators in Germany. The number of prevalent and incident infections is consistent with other data sources and we were able to estimate the number of persons tested for hepatitis, addressing an important data gap. Claims data complement current surveillance systems and provide information for targeted public health action. The established approach should be applied to generate further hepatitis monitoring indicators. Trial registration: Clinical trial number: Not applicable.
- 2 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1) , 1087
Open AccessGenerating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016–2021
Background: Hepatitis B virus (HBV) infection remains one of the most common infectious diseases globally and can be exacerbated by coinfection with hepatitis D virus (HDV). In Germany, the incidence of hepatitis is reported annually through mandatory notification data. Nevertheless, these data lack information on hepatitis prevalence and testing coverage. We evaluated whether statutory health insurance claims data are suitable for continuous monitoring of key hepatitis indicators and whether they can complement existing HBV and HDV surveillance with reliable, population-based estimates. Methods: We conducted a population-based cohort study using anonymised claims data from an age- and gender-representative sample from the InGef (Institute for Applied Health research) database between 2016 and 2021. We retrospectively analysed monitoring indicators for HBV and HDV -including annual prevalent infections within the respective analysis year, incidence of newly detected HBV infections (defined using a 3-year diagnosis-free interval) and the number of persons tested- based on coded diagnoses among individuals with access to healthcare services. Results were extrapolated to the German total population. Results: Between 1,996 and 2,066 persons per 100,000 population were tested annually for at least one HBV marker (HBsAg or Anti-HBc), with 97% undergoing HBsAg testing only. The proportion of annual prevalent HBV infections ranged from 0.14% to 0.15% between 2016 and 2020. Incidence of newly detected HBV infections (3-year diagnosis-free interval) declined from 13.5 per 100,000 in 2019 to 8.9 per 100,000 in 2020. The proportion of prevalent HDV infections among HBV-positive persons varied from 4.5 to 6.4%. Conclusions: Claims data provide a viable basis for continuous monitoring of selected hepatitis indicators in Germany. The number of prevalent and incident infections is consistent with other data sources and we were able to estimate the number of persons tested for hepatitis, addressing an important data gap. Claims data complement current surveillance systems and provide information for targeted public health action. The established approach should be applied to generate further hepatitis monitoring indicators. Trial registration: Clinical trial number: Not applicable.
- Open Access
- 20 October 2025
- Published by Springer Nature in BMC Research Notes
- Vol. 18 (1) , 1-7
Developing a tailored bio-behavioural survey on viral hepatitis among migrants: mixed-methods preparations for the HepMig pilot study, Germany, July 2022–March 2023
Objective: Migrants in Germany from countries with a high prevalence of viral hepatitis may need improved access to healthcare services but have not been adequately included in health surveys so far. The HepMig pilot study aims to develop and pilot an integrated bio-behavioural survey on viral hepatitis among migrants from high-prevalence countries living in Germany. The design should be robust, acceptable, feasible, non-stigmatising, non-discriminatory, and community-centred. This paper describes the preparatory research that informed the pilot study design. Results: We defined our populations of interest as adults (≥ 18 years) born in Bulgaria, Romania, Russia, Syria, or Türkiye living in Germany, irrespective of current citizenship or residence status. Analysis of sociodemographic data from the Federal Statistical Office (DESTATIS) revealed considerable differences between these populations in age distribution, duration of residence, and geographic distribution in Germany. An inductive analysis of information provided by community experts – who shared the same country of birth and /or history of migration or closely worked with the populations in focus – from clinical medicine, academia, non-governmental organizations, and public health identified four themes: (i) sampling of heterogeneous populations of interest; (ii) accessibility and trustworthiness as prerequisites for study participation; (iii) opportunities for community engagement and empowerment; and (iv) ethical considerations. Results will inform sampling, recruitment, data collection, and piloting the study design.
- 20 October 2025
- Published by Springer Nature in BMC Research Notes
- Vol. 18 (1) , 1-7
Open AccessDeveloping a tailored bio-behavioural survey on viral hepatitis among migrants: mixed-methods preparations for the HepMig pilot study, Germany, July 2022–March 2023
Objective: Migrants in Germany from countries with a high prevalence of viral hepatitis may need improved access to healthcare services but have not been adequately included in health surveys so far. The HepMig pilot study aims to develop and pilot an integrated bio-behavioural survey on viral hepatitis among migrants from high-prevalence countries living in Germany. The design should be robust, acceptable, feasible, non-stigmatising, non-discriminatory, and community-centred. This paper describes the preparatory research that informed the pilot study design. Results: We defined our populations of interest as adults (≥ 18 years) born in Bulgaria, Romania, Russia, Syria, or Türkiye living in Germany, irrespective of current citizenship or residence status. Analysis of sociodemographic data from the Federal Statistical Office (DESTATIS) revealed considerable differences between these populations in age distribution, duration of residence, and geographic distribution in Germany. An inductive analysis of information provided by community experts – who shared the same country of birth and /or history of migration or closely worked with the populations in focus – from clinical medicine, academia, non-governmental organizations, and public health identified four themes: (i) sampling of heterogeneous populations of interest; (ii) accessibility and trustworthiness as prerequisites for study participation; (iii) opportunities for community engagement and empowerment; and (iv) ethical considerations. Results will inform sampling, recruitment, data collection, and piloting the study design.
- Open Access
- 19 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0330210
Comparison of registered and survey-based modes of HIV transmission in 2021–2023: Cross-sectional study in the Kyrgyz Republic
Background: Accurate identification of the mode of transmission (MoT) of HIV is critical for effective prevention. However, stigma associated with behaviors such as injecting drug use (IDU) and sex between men (MSM) can lead to misclassification of MoT data. This study replicates the methodology used in Ukraine to assess MoT misclassification and trends in Kyrgyzstan, with the aim of informing evidence-based epidemic control strategies. Methods: A cross-sectional survey was conducted among patients diagnosed with HIV in the six largest administrative units of Kyrgyzstan during the first three quarters of 2021–2023. The survey assessed pre-seroconversion HIV risk factors using self-administered, interviewer-assisted questionnaires, and HCV testing. The McNemar test compared registered and survey-based MoT, while logistic regression analyzed MoT trends over time. Results: A total of 1,962 new HIV diagnoses were registered in the study period, of them 480 individuals completed the survey. The proportion of cases attributable to IDU and MSM was higher in the survey than in the registration system (8.1% vs. 4.2%, p = 0.001 for IDU; 14.2% vs. 11.7% p = 0.12, for MSM), whereas heterosexual MoT was lower (76.0% vs. 80.2%, p = 0.038). Selling sex was reported by 2.9%, and in combination with IDU and MSM, 23.5% of participants could be categorized into one of the three key populations. An additional 18.1% belonged to bridge populations. There was a 23% increase in the absolute number of registered patients in the corresponding periods over three years, but the MoT distribution did not change. Conclusion: We found significant misclassification in IDU and heterosexual MoT, but not in MSM, possibly due to suboptimal survey sensitivity amid the increased stigmatization of the LGBTQI+ community. At least 41% of newly registered cases in Kyrgyzstan occurred in key and bridge populations, highlighting the need for intensified prevention efforts in these groups. Understanding the mode of transmission (MoT) of HIV among newly diagnosed people living with HIV (PLHIV) is critical for monitoring the epidemic and targeting prevention efforts [1]. Assessment of MoT often relies on self-reporting of HIV risk behaviors by patients, which can be inaccurate, especially when associated with stigma or criminalization [2–4]. This is particularly true for injecting drug use (IDU), which is criminalized and stigmatized in many countries [5,6]. Stigma and discrimination against men who have sex with men (MSM) exist in many parts of the world [7,8], leading to underreporting of this behavior even in settings with increasing acceptance [9]. Misclassification of MoT in HIV surveillance systems may be exacerbated by the lack of standardized tools to collect sensitive information or by clinicians’ reluctance to inquire about behaviors that have no impact on patient management.
- 19 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0330210
Open AccessComparison of registered and survey-based modes of HIV transmission in 2021–2023: Cross-sectional study in the Kyrgyz Republic
Background: Accurate identification of the mode of transmission (MoT) of HIV is critical for effective prevention. However, stigma associated with behaviors such as injecting drug use (IDU) and sex between men (MSM) can lead to misclassification of MoT data. This study replicates the methodology used in Ukraine to assess MoT misclassification and trends in Kyrgyzstan, with the aim of informing evidence-based epidemic control strategies. Methods: A cross-sectional survey was conducted among patients diagnosed with HIV in the six largest administrative units of Kyrgyzstan during the first three quarters of 2021–2023. The survey assessed pre-seroconversion HIV risk factors using self-administered, interviewer-assisted questionnaires, and HCV testing. The McNemar test compared registered and survey-based MoT, while logistic regression analyzed MoT trends over time. Results: A total of 1,962 new HIV diagnoses were registered in the study period, of them 480 individuals completed the survey. The proportion of cases attributable to IDU and MSM was higher in the survey than in the registration system (8.1% vs. 4.2%, p = 0.001 for IDU; 14.2% vs. 11.7% p = 0.12, for MSM), whereas heterosexual MoT was lower (76.0% vs. 80.2%, p = 0.038). Selling sex was reported by 2.9%, and in combination with IDU and MSM, 23.5% of participants could be categorized into one of the three key populations. An additional 18.1% belonged to bridge populations. There was a 23% increase in the absolute number of registered patients in the corresponding periods over three years, but the MoT distribution did not change. Conclusion: We found significant misclassification in IDU and heterosexual MoT, but not in MSM, possibly due to suboptimal survey sensitivity amid the increased stigmatization of the LGBTQI+ community. At least 41% of newly registered cases in Kyrgyzstan occurred in key and bridge populations, highlighting the need for intensified prevention efforts in these groups. Understanding the mode of transmission (MoT) of HIV among newly diagnosed people living with HIV (PLHIV) is critical for monitoring the epidemic and targeting prevention efforts [1]. Assessment of MoT often relies on self-reporting of HIV risk behaviors by patients, which can be inaccurate, especially when associated with stigma or criminalization [2–4]. This is particularly true for injecting drug use (IDU), which is criminalized and stigmatized in many countries [5,6]. Stigma and discrimination against men who have sex with men (MSM) exist in many parts of the world [7,8], leading to underreporting of this behavior even in settings with increasing acceptance [9]. Misclassification of MoT in HIV surveillance systems may be exacerbated by the lack of standardized tools to collect sensitive information or by clinicians’ reluctance to inquire about behaviors that have no impact on patient management.